As per the report titled ’ Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)’, available with Market Study Report, global invasive fungal infection (IFI) market was valued at USD 6103.5 million in the year 2018, and is poised to garner immense traction over 2019-2024.
 

Increasing pervasiveness of HIV/AIDS, advancements in drugs and facilities provided by hospitals in ICUs, upsurge in chemotherapy, rising use of broad-spectrum antibiotics, and widespread economic growth are slated to propel the market growth. Additionally, demand for reasonably priced products and usage of broad-spectrum antibiotics which makes fungi resistant to antibiotics, and opting for low-cost medicines which are effective for a longer time is further projected to stimulate market expansion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2459407/
 

Numerous companies are offering a wide range of antibiotics which has decreased the resistance of medicines, in turn, increasing the risk of fungal infection. Also, increasing investments by major manufacturers to develop low-cost products coupled with favorable government initiatives regarding spreading awareness on the measure taken in an ICU are anticipated to boost the market outlook in the approaching years.
 

The well-established companies operating in global invasive fungal infection (IFI) market are F2G- The Rare Fungal Disease Company, Cidara, Basilea Pharmaceutica, Bayer AG, GlaxoSmith Kline, Abott, Astellas Pharma Inc., Merck & Co., Pfizer, and Scynexis Inc. among others.